Othman Al-Sawaf, MD

Panelists comment on the increasing preference for fixed-duration therapy over treatment until progression, as reflected in recent guideline updates.

Panelists discuss the role of non-covalent BTKis in this setting and available supporting data (high level).

Panelists comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data.

Panelists review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy, managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy and defining early versus late relapse.

Panelists discuss the ongoing trials evaluating other BCL2i/BTKi combination approaches.

Panelists review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation.

Panelists discuss the role of ven-ibr in patient populations.

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.

Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.

Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.

Dr Niemann provides an overview of the evolving treatment landscape of CLL.

Othman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses the 5-year follow up data from the phase 3 CLL14 trial (NCT02242942) in patients with previously untreated chronic lymphocytic leukemia (CLL) with preexisting conditions.

Othman Al-Sawaf, MD, discusses the efficacy of venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia, as demonstrated in the phase 3 CLL14 trial.

Othman Al-Sawaf, MD, discusses research efforts that are evaluating the use of venetoclax and obinutuzumab in patients with chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, a physician with the University Hospital of Cologne in Germany, discusses the next steps of the CLL14 trial in chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses the limitations of continuous therapy administration in chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses new safety signals with venetoclax plus obinutuzumab in the phase 3 CLL14 trial.

Othman Al-Sawaf, MD, discusses ongoing minimal residual disease assessment for patients in the phase 3 CLL14 study with chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses benefits of a fixed duration treatment versus continuous treatment in chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses updated data from the phase 3 CLL14 trial in chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses checking complex karyotype in patients with chronic lymphocytic leukemia.